Fusen Pharmaceutical

Company Limited

Fusen Pharmaceutical Co., Ltd. was listed on the main board of the Hong Kong Stock Exchange in 2018, stock code: Based on the traditional Chinese medicine industry, the company is committed ...


Shuanghuanglian Oral Liquid 10*10ml

National essential drugs.National medical insurance class A.

Shuanghuanglian Oral Liquid10*20ml

National essential drugs National medical insurance class A Pediatric non-patented drugs listed directly online

Shuanghuanglian Injection

National medical insurance class B National low-cost drugs

Heat-clearing and Detoxicating Oral Liquid

National medical insurance class B


11 .10

On November 9, Nanyang Enterprise Federation and Entrepreneur Association released the list of "top 50 Nanyang enterprises in 2021" and the list of top 30 Nanyang high growth enterprises in 2021. Henan Fusen Industrial Group Co., Ltd. was listed as "top 50 Nanyang enterprises in 2021".


11 .01

On the 24th, the "rightness and innovation - secondary development of traditional Chinese medicine and large variety cultivation forum" of Fusen pharmaceutical branch of this medical culture festival was held by the beautiful Danjiang lake. Leaders, experts, scholars and medical colleagues from all sides gathered together to give lectures, discuss Taoism, study scriptures, discuss the development plan of traditional Chinese medicine, and join hands to revitalize the health industry of traditional Chinese medicine.


10 .18

Nanning, October 16 (Lin Jieqi) Academician of the Chinese Academy of Engineering and Honorary President of Tianjin University of Traditional Chinese Medicine Zhang Boli stated in Nanning on the 16th that “in the fight against the new crown pneumonia epidemic, the accessibility of traditional Chinese medicine is most worthy of recognition. Under the circumstances, Chinese medicine fights for the vitality of patients and the nation." On the same day, the 2021 academic annual meeting of the Cardiovascular Branch of the Chinese Society of Chinese Medicine was held in Nanning, Guangxi, and Zhang Boli delivered a speech at the meeting. He said that at present, the epidemic situation in various parts of China is still spreading in many places. During the period, the use of traditional Chinese medicine treatment methods has achieved good results in the repeated anti-epidemic tests. Zhang Boli said that the new crown pneumonia epidemic is still in a pandemic. The good news is that in the past more than a month, the epidemic has slowed down globally. The domestic epidemic situation is dynamically cleared, but judging from the outbreaks in Jiangsu, Fujian, Heilongjiang, Inner Mongolia and other places, multiple outbreaks have occurred from time to time. He said that China still needs to tighten the string of epidemic prevention and do a good job of "preventing foreign imports and internal defenses against rebound" and cannot be taken lightly. Zhang Boli said that after TCM syndrome analysis, it is determined that the new coronary pneumonia is a "damp virus disease." Zhang Boli recalled his anti-epidemic experience in Wuhan and said that Chinese medicine emphasizes "dialectical treatment", but Wuhan is a special situation. Faced with thousands of patients, it is impossible to dialectical evidence one by one, and can only adopt similar symptoms caused by the same virus. , Use traditional Chinese medicine to treat. At the same time, the establishment of a system of intervention, the formation of traditional Chinese medicine wards, and the use of integrated traditional Chinese and Western medicine for treatment. Under the emergency situation of the Wuhan epidemic at that time, Zhang Boli and his team could only "build roads with old medicines" and screened nearly 60 kinds of Chinese medicines within 10 days, all of which have a certain inhibitory effect on new coronary pneumonia. At the same time, Jinhua Qinggan Granules, Lianhua Qingwen Capsules, Xuebijing Injection, Qingfei Paidu Recipe, Xuanfei Baidu Recipe, and Huashibaidu Recipe were developed with outstanding effects. "Traditional Chinese medicine has thousands of years of anti-epidemic history. It has summarized a wealth of clinical experience. It is indeed effective and convenient." Zhang Boli said. Traditional Chinese medicine decoctions such as "Maxing Shigan Decoction" and "Maxing Ligan Decoction" are also anti-epidemic. It was widely used during the period. Zhang Boli said that Chinese medicine has played an important role in fighting the epidemic and has also promoted its own development. In order to promote the inheritance and innovation of traditional Chinese medicine, relevant national ministries and commissions have issued plans to focus on supporting the National Traditional Chinese Medicine Center, Regional Traditional Chinese Medicine Medical Centers, National Traditional Chinese Medicine Inheritance Innovation Center, National Traditional Chinese Medicine Epidemic Prevention and Control Base, "flagship" hospitals of collaboration between Chinese and Western medicine, and key hospitals with Chinese medicine characteristics With the construction of the famous doctor hall, Chinese medicine has ushered in new development opportunities. In order to promote the development of traditional Chinese medicine in the post-epidemic era, Zhang Boli stated that it is necessary to create new evidence-based evaluation methods that meet the characteristics of traditional Chinese medicine based on the concept of evidence-based medicine, strengthen the training of integrated Chinese and Western talents, and jointly build and share alliances through Chinese herbal medicine bases to promote standardized cultivation of Chinese medicine , To promote the high-quality development of Chinese medicine.

Industrial segment

Fusen Pharmaceutical Company Limited

Chinese patent medicine and chemical generic drugs. The product treatment field covers the fields of respiratory tract, antiviral infection, cardio cerebrovascular, digestion and metabolism, etc.

Weihai Rensheng Pharmaceutical Company Limited

An important part of the layout of the proprietary Chinese medicine segment, the product treatment fields mainly cover dermatology, orthopedics and pediatrics, with a number of exclusive proprietary Chinese medicine approval numbers.

Sales platform

Jiangxi Yongfeng Kangde Pharmaceutical Co., Ltd.

Agency and promotion services of imported drugs

Jiangxi Ruiyuan Pharmaceutical Co., Ltd.

Agency and promotion services of clinical drugs

R & D platform

Beijing Sanye mingming Pharmaceutical Technology Co., Ltd

Nanjing Puji Pharmaceutical Technology Co., Ltd

Fusen (Shenzhen) biomedical R & D Co., Ltd

Fusen (Hengqin) traditional Chinese medicine R & D company

Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd

Jiangsu Puji Pharmaceutical Technology Co., Ltd

Fusen Pharmaceutical (Macao) Co., Ltd




Copyright © 2021 Fusen Pharmaceutical Company Limited

豫ICP备2021028871号  Powered by

Copyright © 2021 Fusen Pharmaceutical  All Rights Reserved.      豫ICP备2021028871号        Powered by